Elucidation of mechanisms of steatosis and inflammation by alcohol ingestion or HCV core protein

阐明酒精摄入或 HCV 核心蛋白引起的脂肪变性和炎症机制

基本信息

  • 批准号:
    11470040
  • 负责人:
  • 金额:
    $ 9.28万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

This research project is composed of two independent studies, both of which closely relate each other through the common mediator, peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor. The former study describes as follows : Peroxisome proliferator-activated receptor alpha (PPARα)-null mice were fed a liquid diet containing 4% (w/v) ethanol. After 6 months of this diet, all the mice suffered from severe hepatic abnormalities. The features observed in the livers of these mice, e.g., hepatic steatosis, inflammation, apoptosis, fibrosis, hepatomegaly and mitochondrial swelling, resembled the features of alcoholic liver injury in humans. The mice used in this study would seem to constitute a very useful experimental model of alcoholic damage. The results of this study suggest that the onset of hepatic abnormalities is associated with cell damage due to increases in acetaldehyde or oxidative stresses, and with the promotion of hepatocyte proliferation and other phenomena due to altered expression in growth factors or cell cycle regulators. On the other hand, the latter study describes as follows : To clarify the role of hepatitis C virus in hepatocarcinogenesis, we analyzed mice carrying the HCV core gene, which developed hepatic steatosis and hepatocellular carcinoma. The peroxisome proliferator activated receptor a content in hepatocyte nuclei increased due to its stabilization through an interaction with HCV core protein. Additionally, its functiotnal activation occurred in some particular hepatocytes male-specifically, which stimulated functions of oncogene products and cell cycle regulators, and subsequently caused occurrence of aberrant cells, accompanying outstanding accumulation of PPAR, cyclin D1 and so on in nucleus. These aberrant. cells proliferated and had a tendency to form preneoplastic clusters age-dependently. These results suggest a novel mechanism of multicentric hepatocarcinogenesis through PPARα during persistent HCV infedion.
该研究项目由两项独立研究组成,两项研究都通过公共介体,过氧化物体增生剂激活的受体α(PPARα)(核受体)密切相互关联。前一项研究描述的如下:过氧化物体增殖物激活的受体α(PPARα)null小鼠被喂食含有4%(w/v)乙醇的液体饮食。饮食六个月后,所有小鼠患有严重的肝异常。在这些小鼠的生活中观察到的特征,例如肝脂肪变性,感染,凋亡,纤维化,肝肿大和线粒体吞咽,类似于人类酒精肝损伤的特征。这项研究中使用的小鼠似乎构成了酒精损害的非常有用的实验模型。这项研究的结果表明,由于乙醛或氧化应激的增加以及肝细胞增殖的促进和其他现象,由于生长因子或细胞周期调节剂的表达改变而引起的肝细胞增殖和其他现象,肝脏异常的发作与细胞损伤有关。另一方面,后来的研究描述为:为了阐明丙型肝炎病毒在肝癌发生中的作用,我们分析了携带HCV核心基因的小鼠,后者发展了肝脂肪变性和肝细胞癌。过氧化物组激活的受体A在肝细胞核中激活的受体A含量通过与HCV核心蛋白的相互作用而增加。此外,其功能性激活发生在某些特定的肝细胞中,刺激了癌基因产物和细胞周期调节剂的功能,随后引起异常细胞的发生,参与了PPAR的未来积累,细胞周期蛋白D1等在核心中。这些异常。细胞增殖,并具有依赖年龄依赖性的质塑料簇的趋势。这些结果表明,在持续性HCV INFEDION期间,通过PPARα的多中心肝癌发生了一种新的机制。

项目成果

期刊论文数量(48)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Aoyama Toshifumi: "PPARα-null mice."Internal Medicine. vol.8. 588-594 (1999)
Aoyama Toshifumi:“PPARα 缺失小鼠”,内科医学,第 8 卷(1999 年)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
青山俊文: "PPARαの欠損マウス"内分泌・糖尿病科. 8・6. 588-594 (1999)
Toshifumi Aoyama:“PPARα缺陷小鼠”内分泌和糖尿病系8・6(1999)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
青山俊文: "PPARと高脂血症"Tokyo Tanabe Quarterly. 44. 176-183 (1999)
青山俊文:“PPAR 与高脂血症”《东京田边季刊》44. 176-183 (1999)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
青山俊文: "転写因子と高脂血症-PPAR"Molecular Medicine. 37・1. 40-45 (2000)
Toshifumi Aoyama:“转录因子和高脂血症-PPAR”《分子医学》37・1(2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Aoyama Toshifumi: "PPAR and disease."The Cell. vol.31. 218-222 (1999)
青山俊文:“PPAR 与疾病。”细胞。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AOYAMA Toshifumi其他文献

AOYAMA Toshifumi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AOYAMA Toshifumi', 18)}}的其他基金

Elucidation of mechanism on hepatitis C-related liver cancer exacerbation by trans-fatty acid toxicity and development of preventive method
反式脂肪酸毒性导致丙型肝炎相关肝癌恶化的机制的阐明及预防方法的开发
  • 批准号:
    16K08616
  • 财政年份:
    2016
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of prevention methods for hepatitis C - related liver tumor focusing function of nuclear receptor PPAR
以核受体PPAR功能为重点的丙型肝炎相关肝脏肿瘤预防方法的开发
  • 批准号:
    22390060
  • 财政年份:
    2010
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidation of molecular mechanisms for alcohol-dependent inflammatory disorders in digestive tract and liver and development of their preventive methods
消化道和肝脏酒精依赖性炎症性疾病的分子机制的阐明及其预防方法的开发
  • 批准号:
    19590301
  • 财政年份:
    2007
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Transfer of overexpressed protein into organelle and its regulation mechanism
过表达蛋白转入细胞器及其调控机制
  • 批准号:
    04680157
  • 财政年份:
    1992
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Cerebrovascular mitochondria as mediators of neuroinflammation in Alzheimer's Disease
脑血管线粒体作为阿尔茨海默病神经炎症的介质
  • 批准号:
    10723580
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
The role of human SLE causal variant NCF1.pR90H in promoting kidney damage
人类SLE致病变异N​​CF1.pR90H在促进肾脏损伤中的作用
  • 批准号:
    10740630
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
Elucidating function of disease-related SAMD9L mutations in hematopoiesis
阐明疾病相关 SAMD9L 突变在造血中的功能
  • 批准号:
    10644725
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
Correction of diabetic retinopathy by mitochondrial transfer
通过线粒体转移纠正糖尿病视网膜病变
  • 批准号:
    10658455
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
The Role of MICU3 in Alzheimer's Disease Pathogenesis
MICU3 在阿尔茨海默病发病机制中的作用
  • 批准号:
    10677454
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了